Volume 86, Issue 3
Reports

Influence of CYP3A and CYP2C19 Genetic Polymorphisms on the Pharmacokinetics of Cilostazol in Healthy Subjects

H‐D Yoo

College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University, Gwangju, Korea

Search for more papers by this author
S‐A Park

College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University, Gwangju, Korea

Search for more papers by this author
H‐Y Cho

General Pharmacology Team, Pharmacological Research Department, National Institute of Toxicological Research, Korea Food and Drug Administration, Seoul, Korea

Search for more papers by this author
Y‐B Lee

College of Pharmacy and Institute of Bioequivalence and Bridging Study, Chonnam National University, Gwangju, Korea

Search for more papers by this author
First published: 10 June 2009

Abstract

The objective of this study was to investigate the influence of genetic polymorphisms in the CYP3A and CYP2C19 genes on cilostazol pharmacokinetics, with the drug being administered orally as a 50‐mg single dose in healthy subjects. CYP2C19 genotypes in individuals with the CYP3A5*3/*3 genotype were associated with statistically significant differences (P < 0.05) in cilostazol pharmacokinetics parameters (apparent oral clearance (CL/F) and terminal half‐life (t1/2)). This indicates that CYP2C19 polymorphisms play an important role in the metabolism of cilostazol only in individuals with the CYP3A5*3/*3 genotype, which has low metabolic activity.

Clinical Pharmacology & Therapeutics (2009); 86 3, 281–284. doi:10.1038/clpt.2009.90